Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Amgen Inc. before investing.

In this article, we go over a few key elements for understanding Amgen Inc.’s stock price such as:

• Amgen Inc.’s current stock price and volume
• Why Amgen Inc.’s stock price changed recently
• Upgrades and downgrades for AMGN from analysts
• AMGN’s stock price momentum as measured by its relative strength

About Amgen Inc. (AMGN)

Before we jump into Amgen Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Want to learn more about Amgen Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Amgen Inc..

Amgen Inc.’s Stock Price as of Market Close

As of August 21, 2026, 11:45 AM, CST, Amgen Inc.’s stock price was $439.900.

Amgen Inc. is up 1.42% from its previous closing price of $433.730.

During the last market session, Amgen Inc.’s stock traded between $429.380 and $440.510. Currently, there are approximately 540.00 million shares outstanding for Amgen Inc..

Amgen Inc.’s price-earnings (P/E) ratio is currently at 27.0, which is high compared to the Biotechnology industry median of 19.1. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Amgen Inc. Stock Price History

Amgen Inc.’s (AMGN) price is currently up 14.21% so far this month.

During the month of August, Amgen Inc.’s stock price has reached a high of $443.200 and a low of $375.960.

Over the last year, Amgen Inc. has hit prices as high as $443.200 and as low as $269.770. Year to date, Amgen Inc.’s stock is up 34.4%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Amgen Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 20, 2026, there were 0 analysts who downgraded Amgen Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Amgen Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Amgen Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Amgen Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Amgen Inc. (AMGN) by visiting AAII Stock Evaluator.

Relative Price Strength of Amgen Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 20, 2026, Amgen Inc. has a weighted four-quarter relative price strength of 10.09%, which translates to a Momentum Score of 81 and is considered to be Very Strong.

Want to learn more about how Amgen Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Amgen Inc. Stock Price: Bottom Line

As of August 21, 2026, Amgen Inc.’s stock price is $439.900, which is up 1.42% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Amgen Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.